Physician profile
Robert Mcgowin
NPI 1598340887
$1,359.84
in general payments reported to CMS, 2019-2025
23 companies · $694 in 2025
The $694 reported for 2025 was more than what 77% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13.31 · 2022: $160 · 2023: $174 · 2024: $318 · 2025: $694.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,186.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $389.77 | 2023-2025 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $138.56 | 2024-2025 | Ingrezza |
| Novo Nordisk INC | $134.64 | 2023-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $117.97 | 2023-2025 | Breztri, Farxiga |
| Abbvie INC. | $116.13 | 2022-2025 | |
| Lilly USA, LLC | $76.37 | 2022-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $43.12 | 2022-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $37.64 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.73 | 2025 | Caplyta |
| Amgen INC. | $32.83 | 2024 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $31.14 | 2022 | |
| Kyowa Kirin, INC. | $22.86 | 2024 | Crysvita |
| Organon LLC | $21.31 | 2023 | Nexplanon |
| Astellas Pharma US INC | $21.00 | 2025 | Veozah |
| Avanir Pharmaceuticals, INC. | $19.57 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $17.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.40 | 2023 | |
| Exact Sciences Corporation | $16.80 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.50 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.32 | 2024 | Uzedy |
| Phadia US INC. | $13.31 | 2021 | |
| Axsome Therapeutics, INC. | $12.86 | 2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $12.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mcgowin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.